5.4 DEA Form 106, Loss in Transit & Form 41 Destruction
Key Takeaways
- Under 21 CFR § 1301.76(b), registrants must notify the local DEA Field Division in writing within 1 business day of discovering any theft or significant loss of controlled substances, followed by the electronic submission of DEA Form 106 within 45 days.
- Determining whether a loss is 'significant' requires evaluating six DEA criteria: the specific drug lost, quantity relative to business volume, whether the loss is tied to individual diversion patterns, local illicit market trends, and recurring inventory variance patterns.
- When controlled substances are lost in transit prior to delivery acceptance, the supplier/common carrier is responsible for filing DEA Form 107 (theft/loss of chemical/carrier) or Form 106; once the purchaser signs the delivery receipt, custody transfers and purchaser must report any subsequent loss.
- DEA Form 41 documents the permanent destruction of controlled substances, which must meet the DEA's 'non-retrievable' standard; institutional pharmacies typically transfer obsolete or damaged stock to registered reverse distributors via Form 222 (C-II) or invoices (C-III-V).
- Under 21 CFR § 1306.04, the doctrine of Corresponding Responsibility establishes that a pharmacist shares equal legal liability with the prescriber for knowingly dispensing a controlled substance prescription written outside the usual course of professional medical practice.
5.4 DEA Form 106, Loss in Transit & Form 41 Destruction
Quick Answer: Registrants discovering a theft or significant loss of controlled substances must provide written notification to the local DEA Field Division within one (1) business day, followed by the formal electronic submission of DEA Form 106 within 45 calendar days (21 CFR § 1301.76(b)). Determining "significant loss" relies on six statutory evaluation factors. Expired or unneeded controlled substances must be destroyed to a non-retrievable standard or transferred to a registered Reverse Distributor using DEA Form 41 (21 CFR Part 1317). Pharmacists maintain a Corresponding Responsibility (21 CFR § 1306.04) to ensure all dispensed prescriptions serve a legitimate medical purpose.
When controlled substances are diverted, lost in commercial transit, stolen in armed robberies, or rendered obsolete, healthcare registrants must comply with strict federal documentation and reporting mandates. Failure to notify the DEA in a timely manner or disposing of controlled substances improperly exposes institutions to civil monetary penalties exceeding $15,000 per violation, loss of registration, and criminal indictment.
Theft and Significant Loss Reporting: DEA Form 106 (21 CFR § 1301.76(b))
Under federal regulation 21 CFR § 1301.76(b), a DEA registrant must implement a rigorous two-phase reporting process whenever they discover a theft or significant loss of controlled substances.
┌─────────────────────────────────────────────────────────────────────────────┐
│ THE TWO-PHASE THEFT & LOSS TIMELINE │
│ │
│ [ EVENT DISCOVERY ] │
│ │ │
│ ▼ (Within 1 Business Day) │
│ [ PHASE 1: INITIAL NOTIFICATION ] │
│ • Provide formal written notice to the local DEA Field Division │
│ • Notify local law enforcement (police) │
│ • Notify State Board of Pharmacy (per state statutory rules) │
│ │ │
│ ▼ (Conduct Internal Investigation - Up to 45 Calendar Days) │
│ [ PHASE 2: FORMAL ELECTRONIC SUBMISSION ] │
│ • Submit Electronic DEA Form 106 via the secure DEA Web Portal │
│ • Detail exact National Drug Codes (NDCs), quantities, dosage forms │
│ • Specify diversion methodology, physical security breaches, police report │
│ • (If investigation reveals NO loss occurred, send written notice to DEA) │
└─────────────────────────────────────────────────────────────────────────────┘
The Two-Phase Statutory Timeline
- Phase 1: Initial Written Notification within 1 Business Day:
- The registrant must notify the local DEA Diversion Field Office in writing (via official web portal, encrypted email, or fax) within one (1) business day of discovery of any theft or significant loss.
- Registrants should also notify local municipal police departments and their state board of pharmacy.
- Phase 2: Electronic DEA Form 106 Submission within 45 Days:
- Under DEA's 2023 theft-and-loss final rule, the registrant must file a complete and accurate DEA Form 106 through DEA's secure Theft/Loss Reporting (TLR) network application within 45 calendar days after discovery of the theft or loss — the clock runs from discovery, not from the date the initial notice was sent. That window exists so the registrant can conduct an exhaustive internal investigation, reconcile automated dispensing logs, and interview staff before making a final determination. DEA stopped accepting hardcopy DEA Form 106 submissions on July 24, 2023.
- If the investigation reveals that no theft or significant loss actually occurred (e.g., the missing stock was located in another drawer or was an administrative miscount), the registrant must submit a written explanation to the DEA to formally close out the initial 1-business-day notification.
The Six Statutory Criteria for Determining "Significant Loss"
The DEA does not define an arbitrary, fixed mathematical threshold (such as "any loss over 10 tablets") to define a "significant loss." Instead, 21 CFR § 1301.76(b) mandates that registrants evaluate six specific operational criteria:
┌─────────────────────────────────────────────────────────────────────────────┐
│ SIX CRITERIA FOR SIGNIFICANT LOSS │
│ │
│ 1. SPECIFIC DRUG LOST: Potency, abuse liability, and market demand │
│ (e.g., 5 vials of fentanyl vs. 5 tablets of phenobarbital) │
│ │
│ 2. QUANTITY RELATIVE TO BUSINESS VOLUME: Percentage of inventory │
│ (e.g., 100 tablets in a 500-tablet/yr clinic vs 500,000-tablet/yr hosp) │
│ │
│ 3. ASSOCIATION WITH SPECIFIC INDIVIDUALS: Clustering around employees │
│ (e.g., variances coinciding with one specific nurse's shift) │
│ │
│ 4. PATTERN OF LOSS OVER TIME: Recurring minor discrepancies │
│ (e.g., 2 tablets missing every Friday afternoon for 6 months) │
│ │
│ 5. LIKELIHOOD OF DIVERSION: Tampering, punctured seals, saline dilution │
│ (e.g., evidence of needle puncture marks on anesthesia vials) │
│ │
│ 6. LOCAL ILLICIT MARKET TRENDS: High street resale value or epidemic │
│ (e.g., high local demand for oxycodone 30 mg or fentanyl) │
└─────────────────────────────────────────────────────────────────────────────┘
Spillage, Breakage, and Normal Operational Loss
- Witnessed Breakage / Spillage: If an ampule drops on the floor and shatters, or if a liquid oral solution spills on a counter, and the incident is directly witnessed by two licensed staff members, this is NOT considered a theft or loss under DEA Form 106. The broken glass and residual fluid cannot be diverted. This event is documented on institutional waste logs or DEA Form 41.
- Unwitnessed Disappearance: If an ampule or tablet cannot be physically accounted for and there is no physical wreckage or witnessed breakage, it must be treated as a potential theft/loss and investigated under the 6 criteria.
Loss in Transit & Carrier Reporting: DEA Form 107
When controlled substances are shipped between registrants via commercial logistics carriers (e.g., FedEx, UPS, freight couriers), custody handoffs dictate legal reporting responsibility:
┌─────────────────────────────────────────────────────────────────────────────┐
│ TRANSIT LOSS RESPONSIBILITY MATRIX │
│ │
│ SCENARIO RESPONSIBLE PARTY MANDATED ACTION │
│ ──────── ───────────────── ─────────────── │
│ Loss occurs in transit BEFORE WHOLESALE SUPPLIER Files DEA Form 106 │
│ purchaser signs delivery (Reports to DEA) │
│ │
│ Loss discovered AFTER PURCHASER (PHARMACY) Files DEA Form 106 │
│ purchaser signs delivery bill (Reports to DEA) │
│ │
│ Theft/Loss of LISTED CHEMICALS REGULATED PERSON Files DEA Form 107 │
│ (e.g., pseudoephedrine SLCPs) (seller; supplier if (Oral report ASAP; │
│ lost in transit) written w/in 15 d) │
└─────────────────────────────────────────────────────────────────────────────┘
Core In-Transit Principles
- Pre-Receipt Loss: If a wholesaler dispatches a shipment of 100 bottles of morphine, but the delivery truck arrives with broken seals and only 80 bottles inside, the supplier must report the loss on DEA Form 106 because custody was never legally transferred.
- Post-Receipt Loss: If the receiving pharmacy technician signs the carrier's bill of lading without inspecting the inner cartons, and subsequently discovers that a bottle is missing from an open tote inside the vault, the pharmacy holds legal custody and must file DEA Form 106.
- DEA Form 107 is a different form for a different substance class. It reports theft or loss of listed chemicals, including scheduled listed chemical products (SLCPs) such as pseudoephedrine and ephedrine — which are not controlled substances. It is filed by the regulated person, not by the common carrier: the pharmacy or other regulated seller for losses from its premises, and the supplier for in-transit losses (the importer or exporter for import/export shipments). The process is an oral report to the local DEA Diversion Field Office at the earliest practicable opportunity, followed by a written DEA Form 107 within 15 days of becoming aware of the loss (21 CFR § 1314.15). Section 5.5 covers SLCP sales and reporting in full.
Destruction and Disposal Protocols: DEA Form 41 (21 CFR Part 1317)
Under the Secure and Responsible Drug Disposal Act of 2010 and federal regulations codified in 21 CFR Part 1317, controlled substances must be disposed of using methods that permanently render the medication non-retrievable.
1. The "Non-Retrievable" Standard
Under 21 CFR § 1300.05, a controlled substance is rendered non-retrievable when its physical or chemical state is permanently altered through irreversible destruction, rendering the drug unavailable and unusable for all practical purposes. Incineration in compliance with EPA standards and chemical bonding/digestion (e.g., activated carbon neutralizing devices) satisfy this definition. Discarding controlled substances down sink drains or flushing into municipal sewer systems is strictly prohibited under EPA and state environmental laws.
2. Reverse Distribution Workflow
Healthcare institutions and community pharmacies do not routinely destroy controlled substances on-site. Instead, they transfer expired, damaged, or unneeded stock to a registered DEA Reverse Distributor.
┌─────────────────────────────────────────────────────────────────────────────┐
│ REVERSE DISTRIBUTION TRANSFER STEPS │
│ │
│ 1. Pharmacy segregates expired/damaged stock in locked vault quarantine │
│ 2. For SCHEDULE II: Reverse Distributor issues DEA Form 222 to pharmacy │
│ (Pharmacy acts as supplier; Reverse Distributor acts as purchaser) │
│ 3. For SCHEDULE III–V: Pharmacy transfers stock via commercial Invoice │
│ 4. Reverse Distributor receives stock, destroys to non-retrievable standard│
│ 5. Reverse Distributor submits DEA FORM 41 to the DEA │
└─────────────────────────────────────────────────────────────────────────────┘
Crucial Exam Fact: The reverse distributor, not the pharmacy, completes and submits DEA Form 41 (Registrant Record of Controlled Substances Destroyed) to the DEA after physical destruction is executed. The pharmacy retains the Form 222 copies and invoices documenting the initial transfer to the reverse distributor for at least 2 years.
3. Patient Disposal & Collection Receptacles
Under 21 CFR Part 1317, pharmacies, hospitals, and clinics may modify their DEA registration to become Authorized Collectors and install public collection receptacles (take-back kiosks) for patient medications:
- Receptacles must be securely fastened to a permanent building structure, locked, and situated in immediate view of pharmacy staff.
- Receptacles must utilize an inner liner that is removable, waterproof, tamper-evident, and sealed immediately upon removal by two authorized employees.
- Pharmacy staff are strictly prohibited from touching, counting, or inventorying patient-returned medications before sealing the liner (protecting patient privacy and preventing inventory discrepancy liabilities).
SUPPORT Act & CARA Partial Fill Rules (21 CFR § 1306.13)
Federal legislation—specifically the Comprehensive Addiction and Recovery Act (CARA of 2016) and the SUPPORT for Patients and Communities Act of 2018—modernized the rules governing partial fills of Schedule II controlled substance prescriptions.
| Partial Fill Clinical Scenario | Maximum Allowable Timeframe to Complete Partial Fill | Statutory Requirement / Prescriber Notification |
|---|---|---|
| 1. Patient or Prescriber Request (CARA / SUPPORT Act) | 30 calendar days from the original date the prescription was written (issue date) | Total quantity dispensed across all partial fills cannot exceed total quantity prescribed; permitted in retail and outpatient settings |
| 2. Pharmacy Out-of-Stock (Insufficient Inventory) | 72 hours from the date/time of the partial fill | If remainder is not filled within 72 hours, balance is forfeited; pharmacist must notify prescriber; new prescription required |
| 3. Terminally Ill Patients & Long-Term Care (LTCF) | 60 calendar days from the original date of issue | Pharmacist must document "terminally ill" or "LTCF patient" on prescription; partial dispensing logged incrementally |
The Doctrine of Corresponding Responsibility: 21 CFR § 1306.04
Federal regulation 21 CFR § 1306.04 establishes one of the most critical legal doctrines in pharmacy law: Corresponding Responsibility.
21 CFR § 1306.04(a): "A prescription for a controlled substance to be effective must be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his professional practice. The responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription."
┌─────────────────────────────────────────────────────────────────────────────┐
│ CORRESPONDING RESPONSIBILITY RED FLAGS │
│ │
│ • 'THE HOLY TRINITY': Simultaneous prescribing of an Opioid + │
│ Benzodiazepine + Muscle Relaxant (e.g., Oxycodone + Xanax + Soma) │
│ • GEOGRAPHICAL ANOMALIES: Patient traveling hundreds of miles past dozens │
│ of pharmacies to fill a prescription from an out-of-area clinic │
│ • CASH-ONLY TRANSACTIONS: Patients insisting on paying high cash sums │
│ for expensive C-II opioids despite having active insurance │
│ • PATTERN PRESCRIBING: Multiple unrelated patients presenting identical │
│ cocktail prescriptions from the same prescriber on the same day │
│ • EARLY REFILL DEMANDS: Consistent requests for early refills based on │
│ claims of 'lost', 'stolen', or 'spilled' medication │
└─────────────────────────────────────────────────────────────────────────────┘
A pharmacist or pharmacy technician who knowingly ignores obvious red flags and dispenses an illegitimate controlled substance prescription shares equal legal liability with the rogue prescriber, exposing the facility to federal civil penalties, criminal felony charges, and permanent revocation of DEA registration.
A hospital pharmacy discovers an armed robbery resulting in the theft of 500 tablets of oxycodone 30 mg. Under 21 CFR § 1301.76(b), what is the statutory deadline for the pharmacy to provide its initial written notification to the local DEA Field Division?
When a community pharmacy transfers expired Schedule II controlled substances to a DEA-registered reverse distributor for destruction, which document must be issued by the reverse distributor to authorize the physical transfer of the Schedule II stock?
Under the SUPPORT for Patients and Communities Act and CARA (21 CFR § 1306.13), if a patient requests a partial fill of a written Schedule II prescription for oxycodone, what is the maximum timeframe from the original prescription issue date during which the remaining portions may be dispensed?